The use of PCI to treat stable ischemic heart disease declined considerably after publication of the 2007 COURAGE trial, according to a study published in Circulation: Cardiovascular Quality and Outcomes, but other factors may also have played a role. SCAI fellow Dr. Jeffrey W. Moses of New York-Presbyterian Hospital/Columbia University Medical Center suggests greater scrutiny of PCI, as well as new guidelines and criteria for appropriate use may also have contributed to the decline. The new study also noted a reduction in the geographic variation for PCI use for stable disease relative to acute coronary syndromes.

Full Story:

Related Summaries